Pfizer emergency Supreme Court request
Executive Summary
Pfizer asks the Supreme Court May 29 to vacate the Federal Circuit U.S. Court of Appeals' ruling that its Norvasc patent is invalid until the court takes action on its concurrently filed petition for certiorari. The Federal Circuit denied Pfizer's request for an en banc review of its decision (1"The Pink Sheet" May 28, 2007, p. 23). Pfizer argues that the Federal Circuit "used a flawed analytical framework" in applying the Supreme Court's recent ruling in KSR v. Teleflex as to what constitutes an obvious patent...
You may also be interested in...
Federal Circuit Denies En Banc Review of Norvasc Decision
The pharmaceutical and biotech industries were dealt a blow when the Federal Circuit U.S. Court of Appeals decided not to reconsider its ruling that Pfizer's Norvasc (amlodipine besylate) patent is obvious
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.